Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

NEPHROCARE HEALTH SERVICES LTD.

NSE : NEPHROPLUSBSE : 544647ISIN CODE : INE428V01029Industry : Hospital & Healthcare ServicesHouse : Private

BSE509.1512.75 (+2.57 %)

PREV CLOSE ( ) 496.40

OPEN PRICE ( ) 495.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 19349

TODAY'S LOW / HIGH ( )495.00 513.20

52 WK LOW / HIGH ( )445 517.5

NSE508.5512.25 (+2.47 %)

PREV CLOSE( ) 496.30

OPEN PRICE ( ) 496.30

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 508.55 (1362)

VOLUME 276094

TODAY'S LOW / HIGH( ) 496.30 514.00

52 WK LOW / HIGH ( )446 517.85

Select year

Particulars

Mar 2025

Mar 2024

Mar 2023

Operational & Financial Ratios

Earnings Per Share (Rs)

380.15

200.87

-67.75

CEPS(Rs)

158.15

104.34

40.33

DPS(Rs)

0.00

Book NAV/Share(Rs)

3217.49

2309.53

2167.32

Tax Rate(%)

23.26

-5.95

-37.23

Margin Ratios

Core EBITDA Margin(%)

22.05

17.82

11.11

EBIT Margin(%)

14.33

9.42

1.76

Pre Tax Margin(%)

11.57

5.86

-1.96

PAT Margin (%)

8.88

6.21

-2.70

Cash Profit Margin (%)

18.47

16.12

8.02

Performance Ratios

ROA(%)

7.63

4.91

-1.81

ROE(%)

13.81

9.00

-3.13

ROCE(%)

14.76

8.59

1.31

Asset Turnover(x)

0.86

0.79

0.67

Sales/Fixed Asset(x)

1.22

1.19

1.13

Working Capital/Sales(x)

2.89

3.84

2.92

Efficiency Ratios

Fixed Capital/Sales(x)

0.82

0.84

0.88

Receivable days

113.27

116.42

132.30

Inventory Days

12.69

16.82

21.93

Payable days

172.42

123.18

110.84

Valuation Parameters

PER(x)

0.00

PCE(x)

0.00

Price/Book(x)

0.00

Yield(%)

EV/Net Sales(x)

0.10

0.33

0.43

EV/Core EBITDA(x)

0.42

1.71

3.43

EV/EBIT(x)

0.70

3.51

24.37

EV/CE(x)

0.09

0.29

0.32

M Cap / Sales

0.00

Growth Ratio

Net Sales Growth(%)

33.50

29.47

0.00

Core EBITDA Growth(%)

65.13

100.61

0.00

EBIT Growth(%)

102.98

594.53

0.00

PAT Growth(%)

90.98

398.02

0.00

EPS Growth(%)

89.25

396.48

0.00

Financial Stability Ratios

Total Debt/Equity(x)

0.40

0.60

0.52

Current Ratio(x)

1.92

1.61

1.86

Quick Ratio(x)

1.83

1.50

1.71

Interest Cover(x)

5.20

2.64

0.47

Total Debt/Mcap(x)